A. Compston and A. Coles, Multiple sclerosis, Lancet, vol.372, pp.1502-1519, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00996686

C. Jersild, B. Dupont, T. Fog, G. S. Hansen, L. S. Nielsen et al., Histocompatibilitylinked immune-response determinants in multiple sclerosis, Transplant Proc, vol.5, pp.1791-1797, 1973.

S. Sawcer, R. Franklin, and M. Ban, Multiple sclerosis genetics, Lancet Neurol, vol.13, pp.700-709, 2014.

B. Brynedal, K. Duvefelt, G. Jonasdottir, I. M. Roos, E. Akesson et al., HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis, PLoS ONE, vol.2, p.664, 2007.

M. Wagner, M. Bilinska, A. Pokryszko-dragan, M. Sobczynski, M. Cyrul et al., ALCAM and CD6 -multiple sclerosis risk factors, J Neuroimmunol, vol.276, pp.98-103, 2014.
DOI : 10.1016/j.jneuroim.2014.08.621

W. Lundström, S. Highfill, S. Walsh, S. Beq, E. Morse et al., Soluble IL7Ra potentiates IL-7 bioactivity and promotes autoimmunity, Proc Natl Acad Sci U S A, vol.110, pp.1761-70, 2013.

A. P. Gregory, C. A. Dendrou, K. E. Attfield, A. Haghikia, D. K. Xifara et al., TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis, Nature, vol.488, pp.508-519, 2012.

E. M. Frohman, M. K. Racke, and C. S. Raine, Multiple sclerosis: the plaque and its pathogenesis, N Engl J Med, vol.354, pp.942-55, 2006.

H. Lassmann, W. Brück, and C. Lucchinetti, Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy, Trends Mol Med, vol.7, pp.115-136, 2001.

D. Kidd, F. Barkhof, R. Mcconnell, P. R. Algra, I. V. Allen et al., Cortical lesions in multiple sclerosis, Brain, vol.122, pp.17-26, 1999.

J. W. Peterson, L. Bö, S. Mörk, A. Chang, and B. D. Trapp, Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions, Ann Neurol, vol.50, pp.389-400, 2001.

H. Lassmann and H. Wekerle, Chapter 12 -The pathology of multiple sclerosis, pp.557-99, 2006.

A. Junker, J. Ivanidze, J. Malotka, I. Eiglmeier, H. Lassmann et al., Multiple sclerosis: T-cell receptor expression in distinct brain regions, Brain, vol.130, pp.2789-99, 2007.
DOI : 10.1093/brain/awm214
URL : https://academic.oup.com/brain/article-pdf/130/11/2789/940443/awm214.pdf

C. Skulina, S. Schmidt, K. Dornmair, H. Babbe, A. Roers et al., Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood, Proc Natl Acad Sci U S A, vol.101, pp.2428-2461, 2004.

H. Babbe, A. Roers, A. Waisman, H. Lassmann, N. Goebels et al., Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction, J Exp Med, vol.192, pp.393-404, 2000.

L. S. Madsen, E. C. Andersson, L. Jansson, M. Krogsgaard, C. B. Andersen et al., A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor, Nat Genet, vol.23, pp.343-350, 1999.
DOI : 10.1038/15525

J. R. Oksenberg, M. A. Panzara, A. B. Begovich, D. Mitchell, H. A. Erlich et al., Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis, Nature, vol.362, pp.68-70, 1993.

M. Pette, K. Fujita, B. Kitze, J. N. Whitaker, A. E. Kappos et al., Myelin basic proteinspecific T lymphocyte lines from MS patients and healthy individuals, Neurology, vol.40, pp.1770-1776, 1990.

R. Martin, D. Jaraquemada, M. Flerlage, J. Richert, J. Whitaker et al., Fine specificity and HLA restriction of myelin basic proteinspecific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals, J Immunol, vol.145, pp.540-548, 1990.

K. Berer, M. Mues, M. Koutrolos, Z. A. Rasbi, M. Boziki et al., Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination, Nature, vol.479, pp.538-579, 2011.

J. W. Prineas and R. G. Wright, Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis, Lab Invest, vol.38, pp.409-430, 1978.

B. Ajami, J. L. Bennett, C. Krieger, K. M. Mcnagny, and F. Rossi, Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool, Nat Neurosci, vol.14, pp.1142-1151, 2011.

E. H. Tran, K. Hoekstra, N. Van-rooijen, C. D. Dijkstra, and T. Owens, Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice, J Immunol, vol.161, pp.3767-75, 1998.

A. P. Lieberman, P. M. Pitha, H. S. Shin, and M. L. Shin, Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus, Proc Natl Acad Sci U S A, vol.86, pp.6348-52, 1989.

G. P. Meares, X. Ma, H. Qin, and E. N. Benveniste, Regulation of CCL20 expression in astrocytes by IL-6 and IL-17, Glia, vol.60, pp.771-81, 2012.

D. Huang, F. Shi, J. S. Pien, G. C. Wang, J. Salazar-mather et al., The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system, FASEB J, vol.20, pp.896-905, 2006.

J. Hao, R. Liu, W. Piao, Q. Zhou, T. L. Vollmer et al., Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology, J Exp Med, vol.207, pp.1907-1928, 2010.

F. Shi and Q. Zhou, Natural killer cells as indispensable players and therapeutic targets in autoimmunity, Autoimmunity, vol.44, pp.3-10, 2011.

K. L. Sand, E. Knudsen, J. Rolin, Y. Al-falahi, and A. A. Maghazachi, Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate, Cell Mol Life Sci, vol.66, pp.1446-56, 2009.

L. F. Kastrukoff, N. G. Morgan, D. Zecchini, R. White, A. J. Petkau et al., Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B, Neurology, vol.52, pp.351-360, 1999.

K. Steinbach, M. Piedavent, S. Bauer, J. T. Neumann, and M. A. Friese, Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs, J Immunol, vol.191, pp.4531-4540, 2013.

B. Aubé, S. A. Lévesque, A. Paré, É. Chamma, H. Kébir et al., Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases, J Immunol, vol.193, pp.2438-54, 2014.

T. Ishizu, M. Osoegawa, F. Mei, H. Kikuchi, M. Tanaka et al., Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis, Brain, vol.128, pp.988-1002, 2005.

A. J. Silverman, A. K. Sutherland, M. Wilhelm, and R. Silver, Mast cells migrate from blood to brain, J Neurosci, vol.20, pp.401-409, 2000.

N. Couturier, J. P. Zappulla, V. Lauwers-cances, E. Uro-coste, M. Delisle et al., Mast cell transcripts are increased within and outside multiple sclerosis lesions, J Neuroimmunol, vol.195, pp.176-85, 2008.

J. J. Rozniecki, S. L. Hauser, M. Stein, R. Lincoln, and T. C. Theoharides, Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients, Ann Neurol, vol.37, pp.63-69, 1995.

S. Romagnani, TH1 and TH2 in human diseases, Clin Immunol Immunopathol, vol.80, pp.225-260, 1996.

R. Martin, H. F. Mcfarland, and D. E. Mcfarlin, Immunological aspects of demyelinating diseases, Annu Rev Immunol, vol.10, pp.153-87, 1992.

J. Goverman, Autoimmune T cell responses in the central nervous system, Nat Rev Immunol, vol.9, pp.393-407, 2009.

E. Bettelli, B. Sullivan, S. J. Szabo, R. A. Sobel, L. H. Glimcher et al., Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis, J Exp Med, vol.200, pp.79-87, 2004.

D. J. Cua, J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce et al., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, vol.421, pp.744-752, 2003.

I. A. Ferber, S. Brocke, C. Taylor-edwards, W. Ridgway, C. Dinisco et al., Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE), J Immunol, vol.156, pp.5-7, 1996.

D. O. Willenborg, S. Fordham, C. C. Bernard, W. B. Cowden, and I. A. Ramshaw, IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis, J Immunol, vol.157, pp.3223-3230, 1996.

H. S. Panitch, R. L. Hirsch, J. Schindler, and K. P. Johnson, Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system, Neurology, vol.37, pp.1097-102, 1987.

M. Dettke, P. Scheidt, H. Prange, and H. Kirchner, Correlation between interferon production and clinical disease activity in patients with multiple sclerosis, J Clin Immunol, vol.17, pp.293-300, 1997.

H. F. Petereit, N. Richter, R. Pukrop, and S. Bamborschke, Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients, Mult Scler, vol.6, pp.19-23, 2000.

J. Drulovi-c, M. Mostarica-stojkovi-c, L. C. , Z. Stojsavljevi-c-n, V. Pravica et al., Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients, J Neurol Sci, vol.147, pp.145-50, 1997.

L. Cosmi, L. Maggi, V. Santarlasci, F. Liotta, and F. Annunziato, T helper cells plasticity in inflammation, Cytometry, vol.85, pp.36-42, 2014.

A. Roy, X. Liu, and K. Pahan, Myelin basic proteinprimed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected] integrin, J Biol Chem, vol.282, pp.32222-32254, 2007.

A. Roy and K. Pahan, Myelin basic protein-primed T helper 2 cells suppress microglial activation via alphaVbeta3 integrin: implications for multiple sclerosis, J Clin Cell Immunol, vol.7, p.158, 2013.

R. Pedotti, D. Voss, J. J. Steinman, L. Galli, and S. J. , Involvement of both "allergic'' and "autoimmune'' mechanisms in EAE, MS and other autoimmune diseases, Trends Immunol, vol.24, pp.479-84, 2003.

G. Sabatino, M. Nicoletti, G. Neri, A. Saggini, M. Rosati et al., Impact of IL-9 and IL-33 in mast cells, J Biol Regul Homeost Agents, vol.26, pp.577-86, 2012.

A. Jäger, V. Dardalhon, R. A. Sobel, E. Bettelli, and V. K. Kuchroo, Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes, J Immunol, vol.183, pp.7169-77, 2009.

Y. Zhou, Y. Sonobe, T. Akahori, J. S. Kawanokuchi, J. Noda et al., IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes, J Immunol, vol.186, pp.4415-4436, 2011.

C. L. Langrish, Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham et al., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J Exp Med, vol.201, pp.233-273, 2005.

B. Stockinger, M. Veldhoen, and B. Martin, Th17 T cells: Linking innate and adaptive immunity, Semin Immunol, vol.19, pp.353-61, 2007.

H. H. Hofstetter, K. V. Toyka, M. Tary-lehmann, and P. V. Lehmann, Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice, J Immunol, vol.178, pp.1372-1380, 2007.

I. I. Ivanov, B. S. Mckenzie, L. Zhou, C. E. Tadokoro, A. Lepelley et al., The orphan nuclear receptor RORgt directs the differentiation program of proinflammatory IL-17+ T helper cells, Cell, vol.126, pp.1121-1154, 2006.

Y. Yang, R. Winger, P. W. Lee, P. K. Nuro-gyina, A. Minc et al., Impact of suppressing RORgt in ameliorating central nervous system autoimmunity, Clin Exp Immunol, vol.179, pp.108-126, 2015.

C. Lock, G. Hermans, R. Pedotti, A. Brendolan, E. Schadt et al., Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis, Nat Med, vol.8, pp.500-508, 2002.

V. Brucklacher-waldert, K. Stuerner, M. Kolster, J. Wolthausen, and E. Tolosa, Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis, Brain, vol.132, pp.3329-3370, 2009.

D. Matusevicius, P. Kivisäkk, B. He, N. Kostulas, V. Ozenci et al., Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis, Mult Scler, vol.5, pp.101-105, 1999.

L. Durelli, L. Conti, M. Clerico, D. Boselli, G. Contessa et al., T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta, Ann Neurol, vol.65, pp.499-509, 2009.

J. S. Tzartos, M. A. Friese, M. J. Craner, J. Palace, J. Newcombe et al., Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis, Am J Pathol, vol.172, pp.146-55, 2008.

H. Kebir, I. Ifergan, J. I. Alvarez, M. Bernard, J. Poirier et al., Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis, Ann Neurol, vol.66, pp.390-402, 2009.

K. Hirota, J. H. Duarte, M. Veldhoen, E. Hornsby, Y. Li et al., Fate mapping of interleukin 17-producing T cells in inflammatory responses, Nat Immunol, vol.12, pp.255-63, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00612703

M. Mehling, R. Lindberg, F. Raulf, J. Kuhle, C. Hess et al., Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis, Neurology, vol.75, pp.403-413, 2010.

B. M. Segal, C. S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-gort et al., Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebocontrolled, randomised, dose-ranging study, Lancet Neurol, vol.7, pp.796-804, 2008.

W. Hueber, D. D. Patel, T. Dryja, A. M. Wright, I. Koroleva et al., Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, Sci Transl Med, vol.2, pp.52-72, 2010.

T. Duhen, R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto, Production of interleukin 22 but not interleukin 17 by a subset of human skinhoming memory T cells, Nat Immunol, vol.10, pp.857-63, 2009.

S. Rolla, V. Bardina, D. Mercanti, S. Quaglino, P. Palma et al., Th22 cells are expanded in multiple sclerosis and are resistant to IFN-b, J Leukoc Biol, vol.96, pp.1155-64, 2014.

A. Reboldi, C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli et al., C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE, Nat Immunol, vol.10, pp.514-537, 2009.

J. Río, C. Nos, M. Tintoré, N. Téllez, I. Galán et al., Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients, Ann Neurol, vol.59, pp.344-52, 2006.

M. Sospedra and R. Martin, Immunology of multiple sclerosis, Annu Rev Immunol, vol.23, pp.683-747, 2005.

A. P. Kohm, P. A. Carpentier, and S. D. Miller, Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4+ CD25+ regulatory T cells, Novartis Found Symp, vol.252, pp.45-52, 2003.

J. Reddy, Z. Illes, X. Zhang, J. Encinas, J. Pyrdol et al., Myelin proteolipid proteinspecific CD4+ CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis, Proc Natl Acad Sci U S A, vol.101, pp.15434-15473, 2004.

K. Venken, N. Hellings, K. Hensen, J. Rummens, R. Medaer et al., Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4

, + CD25+ regulatory T-cell function and FOXP3 expression, J Neurosci Res, vol.83, pp.1432-1478, 2006.

P. Putheti, A. Pettersson, M. Soderstrom, H. Link, and Y. M. Huang, Circulating CD4+ CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs, J Clin Immunol, vol.24, pp.155-61, 2004.

U. Feger, C. Luther, S. Poeschel, A. Melms, E. Tolosa et al., Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients, Clin Exp Immunol, vol.147, pp.412-420, 2007.

B. Fritzsching, J. Haas, F. König, P. Kunz, E. Fritzsching et al., Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients, PLoS ONE, vol.6, 2011.

J. Haas, A. Hug, A. Viehöver, B. Fritzsching, C. S. Falk et al., Reduced suppressive effect of CD4+ CD25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis, Eur J Immunol, vol.35, pp.3343-52, 2005.

V. Viglietta, C. Baecher-allan, H. L. Weiner, and D. A. Hafler, Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis, J Exp Med, vol.199, pp.971-980, 2004.

K. Cerosaletti, A. Schneider, K. Schwedhelm, I. Frank, M. Tatum et al., Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients, PLoS ONE, vol.8, 2013.

L. Michel, L. Berthelot, S. Pettré, S. Wiertlewski, F. Lefrère et al., Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis, J Clin Invest, vol.118, pp.3411-3420, 2008.

P. Gourraud, H. F. Harbo, S. L. Hauser, and S. E. Baranzini, The genetics of multiple sclerosis: an up-todate review, Immunol Rev, vol.248, pp.87-103, 2012.

H. Lassmann, Experimental models of multiple sclerosis, Rev Neurol (Paris), vol.163, pp.651-656, 2007.

D. Sun, J. N. Whitaker, Z. Huang, D. Liu, C. Coleclough et al., Myelin antigenspecific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice, J Immunol, vol.166, pp.7579-87, 2001.

B. D. Trapp, L. Bö, S. Mörk, and A. Chang, Pathogenesis of tissue injury in MS lesions, J Neuroimmunol, vol.98, pp.49-56, 1999.

A. Bitsch, J. Schuchardt, S. Bunkowski, T. Kuhlmann, and W. Brück, Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation, Brain, vol.123, pp.1174-83, 2000.

R. Höftberger, F. Aboul-enein, W. Brueck, C. Lucchinetti, M. Rodriguez et al., Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions, Brain Pathol, vol.14, pp.43-50, 2004.

V. Annibali, G. Ristori, D. F. Angelini, B. Serafini, R. Mechelli et al., , p.8

, + T cells bear pathogenetic potential in multiple sclerosis, Brain, vol.134, pp.542-54, 2011.

I. Ifergan, H. Kebir, J. I. Alvarez, G. Marceau, M. Bernard et al., Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on a4 integrin, Brain, vol.134, pp.3560-77, 2011.

C. Malmeström, J. Lycke, S. Haghighi, O. Andersen, L. Carlsson et al., Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF, J Neuroimmunol, vol.196, pp.159-65, 2008.

Y. Zang, S. Li, V. M. Rivera, J. Hong, R. R. Robinson et al., Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis, J Immunol, vol.172, pp.5120-5127, 2004.

H. H. Wang, Y. Q. Dai, W. Qiu, Z. Q. Lu, F. H. Peng et al., Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse, J Clin Neurosci, vol.18, pp.1313-1320, 2011.

E. Billerbeck, Y. Kang, L. Walker, H. Lockstone, S. Grafmueller et al., Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties, Proc Natl Acad Sci U S A, vol.107, pp.3006-3017, 2010.

Z. Illés, M. Shimamura, J. Newcombe, N. Oka, and T. Yamamura, Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system, Int Immunol, vol.16, pp.223-253, 2004.

A. Peterfalvi, E. Gomori, T. Magyarlaki, J. Pal, M. Banati et al., Invariant V 7.2-J 33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells, Int Immunol, vol.20, pp.1517-1542, 2008.

L. Bourhis, L. Guerri, L. Dusseaux, M. Martin, E. Soudais et al., Mucosal-associated invariant T cells: unconventional development and function, Trends Immunol, vol.32, pp.212-220, 2011.

R. Reantragoon, L. Kjer-nielsen, O. Patel, Z. Chen, P. T. Illing et al., Structural insight into MR1-mediated recognition of the mucosal-associated invariant T cell receptor, J Exp Med, vol.209, pp.761-74, 2012.

L. Kjer-nielsen, O. Patel, A. J. Corbett, L. Nours, J. Meehan et al., MR1 presents microbial vitamin B metabolites to MAIT cells, Nature, vol.491, pp.717-740, 2012.

L. Bourhis, L. , M. E. Péguillet, I. Guihot, A. Froux et al., Antimicrobial activity of mucosal-associated invariant T cells, Nat Immunol, vol.11, pp.701-709, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00550333

Y. Miyazaki, S. Miyake, A. Chiba, O. Lantz, and T. Yamamura, Mucosal-associated invariant T cells regulate Th1 response in multiple sclerosis, Int Immunol, vol.23, pp.529-564, 2011.

A. Willing, O. A. Leach, F. Ufer, K. E. Attfield, K. Steinbach et al., CD8(+) MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis, Eur J Immunol, vol.44, pp.3119-3147, 2014.

H. Lassmann, G. Suchanek, and K. Ozawa, Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis, Ann Neurol, vol.36, pp.42-48, 1994.

B. Serafini, B. Rosicarelli, R. Magliozzi, E. Stigliano, and F. Aloisi, Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis, Brain Pathol, vol.14, pp.164-74, 2004.

M. Krumbholz, D. Theil, T. Derfuss, A. Rosenwald, F. Schrader et al., BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma, J Exp Med, vol.201, pp.195-200, 2005.

C. Pitzalis, G. W. Jones, M. Bombardieri, and S. A. Jones, Ectopic lymphoid-like structures in infection, cancer and autoimmunity, Nat Rev Immunol, vol.14, pp.447-62, 2014.

C. F. Lucchinetti, B. Popescu, R. F. Bunyan, N. M. Moll, S. F. Roemer et al., Inflammatory cortical demyelination in early multiple sclerosis, N Engl J Med, vol.365, pp.2188-97, 2011.

B. Obermeier, R. Mentele, J. Malotka, J. Kellermann, T. Kümpfel et al., Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis, Nat Med, vol.14, pp.688-93, 2008.

L. M. Villar, M. C. Sádaba, E. Roldán, J. Masjuan, P. González-porqué et al., Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS, J Clin Invest, vol.115, pp.187-94, 2005.

M. Reindl, D. Pauli, F. Rostásy, K. Berger, and T. , The spectrum of MOG autoantibody-associated demyelinating diseases, Nat Rev Neurol, vol.9, pp.455-61, 2013.

D. K. Sato, D. Callegaro, L. , M. A. Waters, P. J. et al., Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders, Neurology, vol.82, pp.474-81, 2014.

R. Srivastava, M. Aslam, S. R. Kalluri, L. Schirmer, D. Buck et al., Potassium channel KIR4.1 as an immune target in multiple sclerosis, N Engl J Med, vol.367, pp.115-138, 2012.

A. Brickshawana, S. R. Hinson, M. F. Romero, C. F. Lucchinetti, Y. Guo et al., Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study, Lancet Neurol, vol.13, pp.795-806, 2014.

N. Molnarfi, U. Schulze-topphoff, M. S. Weber, J. C. Patarroyo, T. Prod'homme et al., MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies, J Exp Med, vol.210, pp.2921-2958, 2013.

T. A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch et al., B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells, J Exp Med, vol.209, pp.1001-1011, 2012.

B. C. Kieseier and O. Stüve, A critical appraisal of treatment decisions in multiple sclerosis: old versus new, Nat Rev Neurol, vol.7, pp.255-62, 2011.

I. Bartholomäus, N. Kawakami, F. Odoardi, C. Schläger, D. Miljkovic et al.,

, Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions, Nature, vol.462, pp.94-102, 2009.

O. Stüve, C. M. Marra, K. R. Jerome, L. Cook, P. D. Cravens et al., Immune surveillance in multiple sclerosis patients treated with natalizumab, Ann Neurol, vol.59, pp.743-750, 2006.

I. J. Koralnik, Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?, Ann Neurol, vol.60, pp.162-73, 2006.

V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder et al., Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis, Nat Rev Drug Discov, vol.9, pp.883-97, 2010.